Global Cancer Vaccine Market (2025 Edition): Analysis By Type (Preventative, Therapeutic), By Technology Type, By Region, By Country: Market Insights and Forecast (2021-2031)

Executive Summary

Azoth Analytics has released a research report titled “Global Cancer Vaccine Market (2025 Edition)” which provides a complete analysis of the Global Cancer Vaccine industry in terms of market segmentation By Type (Preventative, Therapeutic), By Technology Type (Recombinant Vaccine, Whole cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Other Technologies) for the historical period of 2021-2024, the estimates of 2025 and the forecast period of 2026-2031.

The report analyses the Cancer Vaccine Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). The Global Cancer Vaccine market showcased growth at a CAGR of 6.68% during 2021-2024. The market was valued at USD 12165.62 Million in 2024 which is expected to reach USD 20883.55 Million in 2031.

The Cancer Vaccine Market is driven by innovations in immuno-oncology, increased prevalence of cancer, and growing investment in personalized medicine and biologics.

Preventative vaccines continue to dominate market share, particularly due to the success of HPV vaccination campaigns and government-supported immunization initiatives. Therapeutic vaccines are also witnessing increased adoption owing to advances in precision immunotherapy and their potential to treat a broad range of cancers by stimulating the patient’s immune response.

From a technology perspective, Recombinant Vaccines hold a major share in the market, fueled by their high efficacy, safety profile, and increasing R&D activities. Other emerging platforms such as viral vector-based and DNA-based vaccines are gaining traction, especially in clinical development pipelines.

Regionally, Americas leads the market, attributed to the presence of advanced healthcare infrastructure, high awareness, and strong regulatory support for vaccine development. However, Asia Pacific is expected to experience the fastest growth rate during the forecast period, driven by rising cancer incidence, increasing healthcare expenditure, and expanding biotechnology capabilities in countries such as China and India.

Scope of the Report:

• The report analyses the Cancer Vaccine Market by Value (USD Million).
• The report presents the analysis of Cancer Vaccine Market for the historical period of 2021-2024, the estimated year 2025 and the forecast period of 2026-2031.
• The report analyses the Cancer Vaccine Market By Type (Preventative, Therapeutic)
• The report analyses the Cancer Vaccine Market By Technology Type (Recombinant Vaccine, Whole cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Other Technologies).
• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Type, and By Technology Type.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Merck & Co., Inc., Amgen Inc., Bristol Myers Squibb, GSK plc, Moderna, Inc., BioNTech SE, Dendreon Pharmaceuticals LLC, Gritstone bio, Inc., Nouscom S.r.l., and Immunomic Therapeutics, Inc.